---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T00:57:53.390878'
end_time: '2025-12-27T01:03:00.373010'
duration_seconds: 306.98
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: TMEM70
  gene_symbol: TMEM70
  uniprot_accession: Q9BUB7
  protein_description: 'RecName: Full=Transmembrane protein 70, mitochondrial {ECO:0000305};
    Flags: Precursor;'
  gene_info: Name=TMEM70 {ECO:0000312|HGNC:HGNC:26050};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the TMEM70 family. .
  protein_domains: TMEM70. (IPR009724); TMEM70/TMEM186/TMEM223. (IPR045325); TMEM70
    (PF06979)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 9
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BUB7
- **Protein Description:** RecName: Full=Transmembrane protein 70, mitochondrial {ECO:0000305}; Flags: Precursor;
- **Gene Information:** Name=TMEM70 {ECO:0000312|HGNC:HGNC:26050};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the TMEM70 family. .
- **Key Domains:** TMEM70. (IPR009724); TMEM70/TMEM186/TMEM223. (IPR045325); TMEM70 (PF06979)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TMEM70" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TMEM70' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TMEM70** (gene ID: TMEM70, UniProt: Q9BUB7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BUB7
- **Protein Description:** RecName: Full=Transmembrane protein 70, mitochondrial {ECO:0000305}; Flags: Precursor;
- **Gene Information:** Name=TMEM70 {ECO:0000312|HGNC:HGNC:26050};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the TMEM70 family. .
- **Key Domains:** TMEM70. (IPR009724); TMEM70/TMEM186/TMEM223. (IPR045325); TMEM70 (PF06979)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TMEM70" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TMEM70' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TMEM70** (gene ID: TMEM70, UniProt: Q9BUB7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity verification: The target matches UniProt Q9BUB7: human TMEM70, a mitochondrial transmembrane protein in the TMEM70 family (PF06979). Recent literature describes TMEM70 as a two-pass inner-membrane protein with matrix-facing N- and C-termini, consistent with UniProt domain/family annotations and a role in ATP synthase biogenesis (see below) (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 7-10).

Comprehensive research report: TMEM70 (UniProt Q9BUB7)

1) Key concepts and definitions (current understanding)
- Gene/protein and localization: TMEM70 encodes an inner mitochondrial membrane protein of about 21 kDa with two transmembrane helices; both termini face the matrix, and a loop faces the intermembrane space (IMM topology deduced by proteomics and topology mapping). This topology situates TMEM70 to act on incoming substrates within the TIM23 import pathway at the IMM (markovic2023subunitcof pages 85-87).
- Molecular function: TMEM70 is an assembly factor of mitochondrial ATP synthase (Complex V), required for the membrane insertion and subsequent assembly of subunit c into the oligomeric c-ring. Loss of TMEM70 primarily reduces assembled ATP synthase with accumulation of the soluble F1 sector, indicating a biogenesis block on the Fo side (markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26).
- Mechanistic role in ATP synthase biogenesis: Experimental evidence supports that TMEM70 facilitates TIM23-dependent import and lateral insertion of the second transmembrane helix (TM2) of subunit c into the IMM; in the absence of TMEM70, a subunit c construct containing only TM2 fails to insert and is degraded. Mechanistic models also propose an oligomeric TMEM70 scaffold that organizes c-ring assembly before engagement with the F1 headpiece (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26).
- Interacting partners and pathway context: TMEM70 interacts with components of the TIM import machinery (e.g., TIMM44, TIMM21) and with TMEM242, another factor acting downstream to protect newly imported subunit c from degradation. Proteomic links to complex I assembly/maintenance (MCIA) have been reported, consistent with secondary complex I reductions upon TMEM70 loss (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 94-97).

2) Recent developments and latest research (2023–2024 focus)
- Mechanistic advances (2023): Mass-spectrometry and targeted interaction studies identified TMEM70 and TMEM242 among the top interactors of subunit c. TMEM70’s central role in inserting subunit c TM2 via the TIM23 pathway was supported by import/assembly assays; TMEM242 binds TMEM70 and likely acts downstream to stabilize c prior to c-ring assembly. C15orf61, identified in screens, does not contribute to ATP synthase assembly (markovic2023subunitcof pages 1-7, markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 85-87).
- Quantitative assembly phenotypes: TMEM70 deficiency leads to a 60–70% decrease in assembled ATP synthase with concomitant F1 accumulation; TMEM242 depletion preferentially reduces assembled complex V and, in complete knockout, can also reduce complexes I and IV (markovic2023subunitcof pages 23-26, markovic2023subunitcof pages 7-10).
- Disease-oriented curation (2024): A systematic review (Aug 2024; Physiological Research; doi:10.33549/physiolres.935407; https://doi.org/10.33549/physiolres.935407) confirms TMEM70’s involvement in c8-ring assembly and F1 association, catalogues at least 20 pathogenic TMEM70 variants, and highlights that nuclear DNA variants account for ~60% (38/63) of variants in isolated ATP synthase deficiency, with TMEM70 representing the majority of nuclear cases (tauchmannova2024variabilityofclinical pages 3-5).
- Genotype–phenotype and markers (2024): Variant mapping shows clustering in the transit peptide/first transmembrane region, at the C-terminus, and at splice sites (including recurrent c.317–2A>G). Clinical markers that may aid early diagnosis include hyperammonemia and hypocitrullinemia in TMEM70 deficiency (tauchmannova2024variabilityofclinical pages 21-22).
- Therapeutic experimentation (2023): In inducible Tmem70 knockout mice, a ketogenic diet extended median survival, modestly increased assembled ATP synthase, and improved respiratory capacity; transgenic data indicate that very small amounts of TMEM70 suffice for full complementation of complex V content/function, supporting gene-therapy feasibility (markovic2023subunitcof pages 94-97, markovic2023subunitcof pages 1-7).

3) Applications and real-world implementations
- Diagnostics and variant interpretation: TMEM70 is established in diagnostic gene panels for mitochondrial disease and isolated ATP synthase deficiency, with biallelic autosomal inheritance patterns curated by platforms such as OpenTargets and clinical genetics resources (OpenTargets Search: -TMEM70). The 2024 review provides a consolidated reference for variant types and clinical suspicion markers that can guide exome/genome interpretation and biochemical screening (tauchmannova2024variabilityofclinical pages 3-5, tauchmannova2024variabilityofclinical pages 21-22).
- Biomarker-informed screening: Hyperammonemia and hypocitrullinemia may serve as supportive early markers in suspected TMEM70-related disease, informing follow-up genetic testing and metabolic management pathways (tauchmannova2024variabilityofclinical pages 21-22).
- Therapeutic strategies under consideration: Nutritional/metabolic modulation (e.g., ketogenic diet) showed preclinical benefit in murine inducible knockout models, motivating careful clinical consideration in selected contexts; the observation that minimal TMEM70 expression can restore ATP synthase supports gene-replacement concepts as longer-term strategies (markovic2023subunitcof pages 94-97, markovic2023subunitcof pages 1-7).

4) Expert opinions and analysis
- Assembly-factor centrality: Convergent evidence positions TMEM70 as the principal nuclear-encoded determinant of ATP synthase assembly among known assembly factors, particularly at the Fo subunit c insertion/c-ring assembly steps; TMEM242 likely assists downstream, while other candidates (e.g., C15orf61) do not appear essential. This hierarchy is consistent with the predominance of TMEM70 variants in human complex V deficiency cohorts (markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26, tauchmannova2024variabilityofclinical pages 3-5).
- Pathway spillover: The frequent secondary impact on complex I in TMEM70 deficiency suggests broader consequences for mitochondrial biogenesis/stability under stress or impaired complex V assembly, mirroring phenotypes seen with other mitochondrial chaperone/assembly disturbances (markovic2023subunitcof pages 94-97).
- Clinical spectrum and prognosis: TMEM70 deficiency presents as a severe neonatal/infantile encephalo-cardio-myopathy with frequent hypertrophic cardiomyopathy and metabolic crises; despite severity, survival into later childhood or beyond is possible in a subset, emphasizing the need for early recognition and supportive care (tauchmannova2024variabilityofclinical pages 21-22, markovic2023subunitcof pages 23-26).

5) Statistics and data from recent studies
- Variants and prevalence within ATP synthase defects: At least 20 pathogenic TMEM70 variants are recorded, with TMEM70 constituting the majority of nuclear-encoded isolated ATP synthase deficiencies; overall, nuclear DNA variants account for ~60% (38/63) of variants in isolated ATP synthase deficiency (Aug 2024 review; doi:10.33549/physiolres.935407) (tauchmannova2024variabilityofclinical pages 3-5).
- Family counts and clinical burden: >20 distinct mutations reported across ~50 families; hypertrophic cardiomyopathy prevalence ~93% in summarized cohorts; approximate 10-year survival ~63% (synthesis from Marković 2023 reporting) (markovic2023subunitcof pages 23-26).
- Quantitative assembly phenotype: Assembled ATP synthase is reduced by approximately 60–70% in TMEM70 deficiency, with accumulation of the F1 sector (markovic2023subunitcof pages 23-26).

6) Disease associations (structured resources)
- OpenTargets disease links: TMEM70 is strongly associated with mitochondrial encephalo-cardio-myopathy due to TMEM70 deficiency (Orphanet_1194), mitochondrial complex V (ATP synthase) deficiency, nuclear type 2 (MONDO_0013546), isolated ATP synthase deficiency (Orphanet_254913), and broader mitochondrial disease categories, with high association scores and evidence curated from Genomics England, Orphanet, EVA and literature; inheritance is biallelic autosomal (OpenTargets Platform; association scores ~0.59–0.85; multiple PMIDs) (OpenTargets Search: -TMEM70).

7) Domain/family alignment and cross-check
- TMEM70 belongs to the TMEM70 family and is predicted to be a two-pass IMM protein; recent experimental topology data match these predictions (matrix-oriented termini), aligning with UniProt domains and the provided family annotations (PF06979/IPR009724) (markovic2023subunitcof pages 85-87).

Open questions and future directions
- Structural mechanism: The precise structural basis for TMEM70’s assistance in TM2 lateral insertion and c-ring nucleation remains to be fully resolved; oligomerization state and transient complexes with subunit c and TMEM242 are priority targets for structural biology (markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26).
- Clinical translation: The preclinical benefits of ketogenic diet in murine models and the demonstration that very low TMEM70 rescues complex V content motivate evaluation of metabolic therapy protocols and gene-replacement approaches in carefully phenotyped patients (markovic2023subunitcof pages 94-97, markovic2023subunitcof pages 1-7).

Key summary table
| Category | Key findings | Quantitative data | Source (year) |
|---|---|---:|---|
| Identity & localization | Transmembrane protein 70 (TMEM70); localizes to inner mitochondrial membrane with matrix-oriented N‑ and C‑termini; predicted two transmembrane helices. | ~21 kDa; 2 TM helices; gene on chr8. | 2023 |
| Molecular function | ATP synthase (Complex V) assembly factor required for incorporation of subunit c and c‑ring formation; deficiency leads to loss of assembled CV and accumulation of F1. | Assembled CV decreased ~60–70%; F1 accumulation observed. | 2023–2024 |
| Specific mechanistic role | Facilitates TIM23‑dependent import / lateral insertion of subunit c TM2 into the inner membrane; may form an oligomeric scaffold for c‑ring assembly; TMEM242 acts downstream to protect subunit c from degradation. | TM2 fails to insert without TMEM70; TMEM242 knockdown lowers assembled CV; TMEM242 KO reduces CI and CIV. | 2023 |
| Interacting partners & pathway notes | Interacts with TIM complex components (e.g., TIMM44, TIMM21), TMEM242; proteomics links to MCIA / Complex I assembly pathways. | Identified among top interactors in mass‑spec/BioID screens. | 2023 |
| Disease associations & genotype–phenotype | Biallelic TMEM70 variants cause mitochondrial encephalo‑cardio‑myopathy: neonatal metabolic crises, hypertrophic cardiomyopathy, LV noncompaction, hypotonia; biochemical markers include hyperammonemia and hypocitrullinemia. | ≥20 pathogenic variants reported; ~50 families described; cardiac involvement ≈93% in cohorts; 10‑yr survival ≈63%. | 2023–2024 |
| Prevalence among ATP synthase defects | TMEM70 is the most frequent nuclear‑encoded cause of isolated ATP synthase deficiency. | Nuclear DNA accounts for ~60% (38/63) of variants in isolated ATP synthase deficiency; TMEM70 represents the majority of nDNA cases. | 2024 |
| Therapeutic & experimental insights | Animal models: transgenic complementation with low TMEM70 restores ATP synthase; inducible Tmem70 KO mice showed improved survival and assembled CV on a ketogenic diet; supports gene‑therapy and metabolic interventions. | Ketogenic diet extended median survival in iTmem70‑/- mice; very low TMEM70 expression sufficient for full complementation in transgenic models. | 2023 |


*Table: Compact, evidence‑based summary of human TMEM70 (UniProt Q9BUB7) covering identity, molecular role in ATP synthase biogenesis, interactors, disease spectrum with quantitative facts, and experimental/therapeutic insights; useful as a quick reference for researchers and clinicians.*

Cited sources with URLs/dates where available
- Tauchmannová K., Pecinová A., Houštěk J., Mrázek T. Variability of Clinical Phenotypes Caused by Isolated Defects of Mitochondrial ATP Synthase. Physiological Research. Aug 2024. doi:10.33549/physiolres.935407; https://doi.org/10.33549/physiolres.935407 (tauchmannova2024variabilityofclinical pages 3-5, tauchmannova2024variabilityofclinical pages 21-22).
- Marković A. Subunit c of mammalian F1Fo ATP synthase—from molecular mechanisms of assembly to potential therapies. 2023 (doctoral thesis/report; mechanistic and experimental insights; contains data on TMEM70/TMEM242 interactions and therapeutic models) (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26, markovic2023subunitcof pages 1-7, markovic2023subunitcof pages 94-97).
- OpenTargets Platform disease-association record for TMEM70 (ENSG00000175606). Accessed via platform evidence (association scores and curated inheritance; 2025 dataset release; specific PMIDs embedded in evidence) (OpenTargets Search: -TMEM70).

References

1. (markovic2023subunitcof pages 85-87): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

2. (markovic2023subunitcof pages 7-10): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

3. (markovic2023subunitcof pages 23-26): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

4. (markovic2023subunitcof pages 94-97): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

5. (markovic2023subunitcof pages 1-7): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

6. (tauchmannova2024variabilityofclinical pages 3-5): K. Tauchmannová, A. Pecinová, J. Houštěk, and T. Mrázek. Variability of clinical phenotypes caused by isolated defects of mitochondrial atp synthase. Physiological Research, pages S243-S278, Aug 2024. URL: https://doi.org/10.33549/physiolres.935407, doi:10.33549/physiolres.935407. This article has 9 citations and is from a peer-reviewed journal.

7. (tauchmannova2024variabilityofclinical pages 21-22): K. Tauchmannová, A. Pecinová, J. Houštěk, and T. Mrázek. Variability of clinical phenotypes caused by isolated defects of mitochondrial atp synthase. Physiological Research, pages S243-S278, Aug 2024. URL: https://doi.org/10.33549/physiolres.935407, doi:10.33549/physiolres.935407. This article has 9 citations and is from a peer-reviewed journal.

8. (OpenTargets Search: -TMEM70): Open Targets Query (-TMEM70, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

## Citations

1. markovic2023subunitcof pages 85-87
2. tauchmannova2024variabilityofclinical pages 3-5
3. tauchmannova2024variabilityofclinical pages 21-22
4. markovic2023subunitcof pages 94-97
5. markovic2023subunitcof pages 23-26
6. markovic2023subunitcof pages 7-10
7. markovic2023subunitcof pages 1-7
8. https://doi.org/10.33549/physiolres.935407
9. https://doi.org/10.33549/physiolres.935407,